Combination vigabatrin and lamotrigine therapy for intractable epilepsy

Area of Science:

• Neurology
• Pharmacology
• Clinical Medicine

Background:

• Vigabatrin (GVG) and lamotrigine (LTG) are established antiepileptic drugs (AEDs) for refractory seizures.
• Individual efficacy of GVG and LTG as add-on therapy is known.
• Limited data exists on the combined use of GVG and LTG.

Purpose of the Study:

• To evaluate the efficacy and safety of combining vigabatrin (GVG) and lamotrigine (LTG) in patients with intractable epilepsy.
• To assess the reduction in monthly seizure frequency (MSF) with the combination therapy.
• To determine the optimal therapeutic window for this combination.

Main Methods:

• Prospective audit of 42 patients with intractable epilepsy.
• Add-on therapy with a combination of GVG and LTG.
• Median treatment period of eight months.
• Monitoring of monthly seizure frequency and adverse events.

Main Results:

• A statistically significant median reduction of 62% in MSF was observed (from 29 to 11).
• 69% of patients (29/42) experienced a greater than 50% reduction in MSF.
• Additional MSF reduction from the combination was 21%.
• Adverse events occurred in 57% of patients, with a 12% drop-out rate.

Conclusions:

• The combination of GVG and LTG is a viable therapeutic option for patients with intractable epilepsy.
• The study supports the need for controlled trials to confirm the additive efficacy of this combination.
• Further research is recommended to optimize dosing and minimize adverse events.